(Alliance News) - Shares in Ixico PLC on Monday rose after the company announced the launch of its new brain segmentation platform IXIQ Ai.
Ixico shares were up 5.7% at 49.68 pence each on Monday morning in London.
The London-based medical imaging company said IXIQ Ai has been developed and validated in collaboration with its academic and pharma partners.
The brain segmentation platform will enable the measurement of some of the brain structures that play a key role in understanding central nervous system diseases.
Furthermore, IXIQ Ai will be applied to clinical trials from March, the company continued.
The launch is expected to coincide with the 17th annual Huntington disease therapeutics conference running February 28 to March 3.
"We are pleased to launch IXIQ Ai into production and see it used on our first clinical trials and would like to thank our collaborators for supporting our thorough development and validation process," Chief Scientific Officer Robin Wolz commented.
He added: "IXIQ Ai is the next generation of Ixico's technology platform that has been continuously invested in, and developed, across more than 10 years: With novel AI tools like deep learning and increasing numbers of curated datasets at our disposal, we are excited to make available this new platform that enables the accurate and automated measurement of some of the most complex brain structures that play a key role in understanding central nervous system diseases."
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Ixico (IXI)